

(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property
Organization
International Bureau



(10) International Publication Number
WO 2022/123221 A1

(43) International Publication Date
16 June 2022 (16.06.2022)

- (51) **International Patent Classification:**
A61K 31/7076 (2006.01) *A61P 37/02* (2006.01)
- (21) **International Application Number:**
PCT/GB2021/053182
- (22) **International Filing Date:**
06 December 2021 (06.12.2021)
- (25) **Filing Language:** English
- (26) **Publication Language:** English
- (30) **Priority Data:**
2019460.1 10 December 2020 (10.12.2020) GB
- (71) **Applicant:** CHORD THERAPEUTICS SA [CH/CH]; 15
avenue de Secheron, 1202 Geneva (CH).
- (72) **Inventor:** REJDAK, Konrad; Organowa 3/20, 20-882
Lublin (PL).
- (74) **Agent:** COLE, Paul; 135 Westhall Road, Warlingham Sur-
rey CR6 9HJ (GB).

- (81) **Designated States** (*unless otherwise indicated, for every kind of national protection available*): AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DJ, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IR, IS, IT, JO, JP, KE, KG, KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, WS, ZA, ZM, ZW.
- (84) **Designated States** (*unless otherwise indicated, for every kind of regional protection available*): ARIPO (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG).

Declarations under Rule 4.17:

— of inventorship (Rule 4.17(iv))

Published:

— with international search report (Art. 21(3))

(54) **Title:** USE OF CLADRIBINE FOR TREATING IMMUNE BRAIN DISEASE

(57) **Abstract:** 2-Chloro-2'-deoxyadenosine, hereinafter referred to as cladribine, or a pharmaceutically acceptable salt thereof may be used in the treatment or amelioration of autoimmune encephalitis, hereinafter referred to as AE, in a patient diagnosed with AE.

WO 2022/123221 A1